Developed human iPS cell-derived cardiomyocytes that reduce immune rejection in cell transplantation, 1 photo, international news

AFPBB News’ international desk reported that human iPS cell-derived cardiomyocytes had been newly developed to reduce immune rejection.

Read in fullFrom the source, not the headline

sources corroborateOutlets reporting the same event

companies linkedAcross 0 themes, second pass

The story

The development of human iPS cell-derived cardiomyocytes aimed at mitigating immune rejection, with a view to the clinical application of cell transplantation, has been reported.

At a glance

TypeNewly developed human iPS cell-derived cardiomyocytes

PurposeMay reduce immune rejection during cell transplantation

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

www.afpbb.comNews

AgreesOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.

Developed human iPS cell-derived cardiomyocytes that reduce immune rejection in cell transplantation, 1 photo, international news | News